Fig. 1: Monocyte and microglial activation in CNS 3 months after LPS administration. | npj Parkinson's Disease

Fig. 1: Monocyte and microglial activation in CNS 3 months after LPS administration.

From: Systemic inflammation accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human alpha synuclein

Fig. 1

a Representative flow cytometry dot plots of isolated cells illustrating the gating strategy to determine profiles based on CD45lowCD11b+ for microglia, CD45highCD11bhigh macrophages for the central nervous system (CNS)-associated phagocytes, and CD45highCD11b− cells. b Percentage of CD45highCD11bhigh cells in the SNpc (left) and in the striatum (right). Error bars represent ±SEM. (n = 5 SAL WT, n = 5 LPS WT, n = 6 SAL Snca+/+, n = 6 LPS Snca+/+; Ordinary two-way ANOVA for Genotype vs Treatment; SNpc: Interaction, F (1, 18) = 0.003483; Genotype, F (1, 18) = 79.06, p < 0.001; Treatment, F (1, 18) = 18.48, p = 0.0004; *p < 0.05, ****p < 0.0001, with Bonferroni’s post hoc multiple comparisons test; striatum: Interaction, F (1, 18) = 0.02436; Genotype, F (1, 18) = 52.37, p < 0.0001; Treatment, F (1, 18) = 13.76, p = 0.0016; ***p < 0.001, ****p < 0.0001, with Bonferroni’s post hoc multiple comparisons test). c Percentage of CD45lowCD11b+ microglia in the SNpc (top) and in the striatum (bottom). Error bars represent ±SEM. (n = 5 SAL WT, n = 5 LPS WT, n = 6 SAL Snca+/+, n = 6 LPS Snca+/+; Ordinary two-way ANOVA for Genotype vs Treatment; SNpc: Interaction, F (1, 18) = 0.7841; Genotype, F (1, 18) = 0.7550; Treatment, F (1, 18) = 9.796, p = 0.0058; striatum: Interaction, F (1, 18) = 0.1473). d Mean fluorescence of CD86 both in the SNpc (top) and striatum (bottom). (n = 5 SAL WT, n = 5 LPS WT, n = 6 SAL Snca+/+, n = 6 LPS Snca+/+; Ordinary two-way ANOVA for Genotype vs Treatment; SNpc: Interaction, F (1, 18) = 2.858; Genotype, F (1, 18) = 79.88, p < 0.0001; Treatment, F (1, 18) = 9.063, p = 0.0075; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, with Bonferroni’s post hoc multiple comparisons test; striatum: Interaction, F (1, 18) = 4.848, p = 0.0410; Genotype, F (1, 18) = 111.9, p < 0.0001; Treatment, F (1, 18) = 25.47, p < 0.0001; **p < 0.01, ***p < 0.001, ****p < 0.0001, with Bonferroni’s post hoc multiple comparisons test). e Mean fluorescence of MHC-II both in the SNpc (top) and striatum (bottom). (n = 5 SAL WT, n = 5 LPS WT, n = 6 SAL Snca+/+, n = 6 LPS Snca+/+; Ordinary two-way ANOVA for Genotype vs Treatment; SNpc: Interaction, F (1, 18) = 0.2921; Genotype, F (1, 18) = 56.27, p < 0.0001; Treatment, F (1, 18) = 623.2, p < 0.0001; ***p < 0.001, ****p < 0.0001, with Bonferroni’s post hoc multiple comparisons test; striatum: Interaction, F (1, 18) = 7.674, p = 0.0126; Genotype, F (1, 18) = 24.36, p = 0.0001; Treatment, F (1, 18) = 40.04, p < 0.0001; ***p < 0.001, ****p < 0.0001, with Bonferroni’s post hoc multiple comparisons test).

Back to article page